Wikipedia -WSS

Wikipedia

author：entertainment 2025-09-27 12:57:22 - browse：9

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Zyn nicotine pouches become unlikely player in latest culture war

WSS

10 reasons why health care startups fail

Venture capital firm's plans to take over Akron hospital face hurdles

New brain studies show LSD's effects on the brain in full color

NIH director takes cautious approach to Biden drug pricing priority

Eli Lilly, Pfizer, and others want in on the online prescription market

Elizabeth Holmes banned from government health programs

Wikipedia

Wikipedia

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

Elizabeth Holmes banned from government health programs

Duchenne breakthrough therapy leaves behind pioneering families

Elizabeth Holmes banned from government health programs

Walensky prepares to leave CDC — and Congress — behind

The surgeon had a dilemma only a Nazi medical text could resolve

Drug repurposing or repositioning? The language matters

EU regulator recommends expanding Mounjaro approval to obesity

DIEP, the 'gold standard' of breast reconstruction, is under threat

Vertex non

knowledge

Biogen walks away from Aduhelm, years after polarizing approval

Syphilis numbers in the United States reach record heights

Humana cuts profit projections as Medicare Advantage costs soar

Merck, Johnson & Johnson CEOs will testify on high drug prices

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

FDA clears AI tool for detecting skin cancer

explore

leisure time

knowledge

focus